Clinical and Safety Outcomes With GLP-1 Receptor Agonists and SGLT2 Inhibitors in Type 1 Diabetes: A Real-World Study

Medicine & Life Sciences

• Sodium-Glucose Transporter 2 Inhibitors 100%
• Sodium-Glucose Transport Proteins 98%
• Glucagon-Like Peptide-1 Receptor 89%
• Type 1 Diabetes Mellitus 61%
• Safety 40%
• Diabetic Ketoacidosis 17%
• Insulin 14%
• Weight Loss 11%
• Hemoglobins 11%
• Physiologic Monitoring 7%
• Glycated Hemoglobin A 7%
• Patient Selection 6%
• Sodium 5%
• Risk Assessment 5%
• Therapeutics 4%
• Glucose 4%

Chemical Compounds

• Agent Interacting With Transmitter, Hormone or Drug Receptor 76%
• Glucagon-Like Peptide-1 Receptor Agonist 67%
• Safety 59%
• Insulin Derivative 52%
• Hemoglobin 48%
• Reduction 31%
• Adjuvant 21%
• Weight 18%
• Dose 13%
• Time 6%